Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 11/20 | 0.82 |
| ▸ | KCNK9 | Q9NPC2 | 9/20 | 0.82 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 4/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 2/20 | 0.65 |
| ▸ | RAB9A | P51151 | 2/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2298254 | 0.91 | KCNK3 (1.00) | KCNK3KCNK9SIRT1MEN1KMT2A | |
| SCHEMBL14715912 | 0.87 | KCNK3 (0.92) | KCNK3KCNK9SIRT1MEN1KMT2A | |
| SCHEMBL14715827 | 0.87 | KCNK3 (0.92) | KCNK3KCNK9SIRT1MEN1KMT2A | |
| SCHEMBL28031075 | 0.86 | KCNK3 (0.77) | KCNK3KCNK9SIRT1MEN1KMT2A | |
| SCHEMBL4004339 | 0.86 | KCNK3 (0.76) | KCNK3KCNK9SIRT1MEN1KMT2A | |
| SCHEMBL18953533 | 0.85 | KCNK3 (0.89) | KCNK3KCNK9SIRT1MEN1KMT2A | |
| SCHEMBL14715832 | 0.85 | KCNK3 (0.88) | KCNK3KCNK9SIRT1MEN1KMT2A | |
| SCHEMBL22699755 | 0.85 | KCNK3 (0.77) | KCNK3KCNK9SIRT1MEN1KMT2A | |
| SCHEMBL22699737 | 0.85 | MEN1 (0.84) | KCNK3KCNK9MEN1KMT2ATP53 | |
| SCHEMBL3690365 | 0.84 | MAPT (0.59) | KCNK3KCNK9MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200369901-A1 | DISPERSION, INK JET RECORDING METHOD, RECORDED MATERIAL, AND COMPOUND | FUJIFILM CORPORATION (JP) | 2020-11-26 | — | — | US | disclosed |
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, KDR | KCNK3 3412/4885KCNK9 2521/4885SIRT1 1656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.